Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.377
Sell
RSI(14)
40.723
Neutral
STOCH(KDJ)(9,3,3)
17.775
Neutral
ATR(14)
1.551
High Vlolatility
CCI(14)
-85.099
Neutral
Williams %R
74.206
Sell
TRIX(12,20)
-0.271
Sell
StochRSI(14)
81.740
Buy
Immunocore Holdings PLC
IMCR31.980USD
+1.060+3.43%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
1.59BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Immunocore Holdings PLC
Currency: USD Updated: 2026-02-06Key Insights
Immunocore Holdings PLC's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 28 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 67.94.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Immunocore Holdings PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Immunocore Holdings PLC Highlights
StrengthsRisks
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a pipeline of clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, ovarian, lung, colorectal and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 77.91% year-on-year.
Fairly Valued
The company’s latest PE is -54.78, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 50.63M shares, decreasing 15.97% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 2.42K shares of this stock.
Analyst Rating
Based on
17
analysts
Buy
Current Rating
67.938
Target Price
+115.67%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Immunocore Holdings PLC is 9.25, ranking 12 out of 159 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 103.69M, representing a year-over-year increase of 29.22%, while its net profit experienced a year-over-year increase of 102.03%.
Score
Financials
8.59
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
10.00
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
7.67
Immunocore Holdings PLC's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Immunocore Holdings PLC is 7.88, ranking 43 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -54.78, which is -49.62% below the recent high of -27.60 and -67.59% above the recent low of -91.80.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 28/159
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Immunocore Holdings PLC is 8.35, ranking 42 out of 159 in the Pharmaceuticals industry. The average price target is 70.00, with a high of 100.00 and a low of 36.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
17
analysts
Buy
Current Rating
67.938
Target Price
+115.67%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
173
Total
6
Median
8
Average
Company name
Ratings
Analysts
Immunocore Holdings PLC
IMCR
17
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Vertex Pharmaceuticals Inc
VRTX
33
Eli Lilly and Co
LLY
33
Gilead Sciences Inc
GILD
31
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Immunocore Holdings PLC is 6.66, ranking 115 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 35.09 and the support level at 29.74, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
31.902
Buy
MA10
32.830
Sell
MA20
33.212
Sell
MA50
35.059
Sell
MA100
34.636
Sell
MA200
33.884
Sell
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of Immunocore Holdings PLC is 10.00, ranking 1 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 101.68%, representing a quarter-over-quarter increase of 2.49%. The largest institutional shareholder is PRIMECAP Management, holding a total of 3.75M shares, representing 7.54% of shares outstanding, with 39.33% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
T. Rowe Price Investment Management, Inc.
RTW Investments L.P.
Wellington Management Company, LLP
Fidelity Management & Research Company LLC
Bellevue Asset Management AG
Tang Capital Management, LLC
Baker Bros. Advisors LP
Deep Track Capital LP
BVF Partners L.P.
1
2
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Immunocore Holdings PLC is 6.26, ranking 57 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.78. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.78
VaR
+4.61%
240-Day Maximum Drawdown
+23.11%
240-Day Volatility
+54.84%
Return
Best Daily Return
60 days
+6.16%
120 days
+9.33%
5 years
+14.93%
Worst Daily Return
60 days
-5.48%
120 days
-5.48%
5 years
-22.09%
Sharpe Ratio
60 days
-0.29
120 days
+0.03
5 years
+0.16
Risk Assessment
Maximum Drawdown
240 days
+23.11%
3 years
+67.45%
5 years
+67.45%
Return-to-Drawdown Ratio
240 days
+0.29
3 years
-0.16
5 years
-0.06
Skewness
240 days
+0.62
3 years
+0.17
5 years
+0.09
Volatility
Realised Volatility
240 days
+54.84%
5 years
+59.94%
Standardised True Range
240 days
+4.97%
5 years
+6.82%
Downside Risk-Adjusted Return
120 days
+7.12%
240 days
+7.12%
Maximum Daily Upside Volatility
60 days
+29.92%
Maximum Daily Downside Volatility
60 days
+26.71%
Liquidity
Average Turnover Rate
60 days
+0.67%
120 days
+0.74%
5 years
--
Turnover Deviation
20 days
-27.80%
60 days
-19.27%
120 days
-10.73%
Peer Comparison
Pharmaceuticals
Immunocore Holdings PLC
IMCR
8.12 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mckesson Corp
MCK
9.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.92 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.86 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.70 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
